Table 1.

COVID-19 patients with malignant conditions treated with ruxolitinib

Reference	N	Malignant condition	Concurrent treatment	Rux dose (mg)
La Rosée [3]	1	Lung cancer	Reconvalescent after surgery	7.5 b.i.d./12 days
Innes [5]	1	CML-BC, Allo-SCT	Corticosteroids, cyclosporin, mycophenolate	5 b.i.d./6 days; 10 b.i.d./15 days
Rojas [4]	2	1 – ALL 2 – Multiple myeloma	1 – Methotrexate phase of BFM chemotherapy 2 – Cyclophosphamide, bortezomib, dexamethasone + radiation therapy	10 b.i.d./1 week; 5 b.i.d./1 week; 5 q.d./2 days
Portsmore [6]	2	Non-Hodgkin lymphoma	1 – high-dose chemotherapy with autologous PBSCT 2 – in remission (9 months)	not reported
Giudice [7]	1	Non-Hodgkin lymphoma	not reported	2×10 b.i.d. for 14 days

BFM, Berlin-Frankfurt-Münster treatment protocol for acute lymphoblastic leukaemia; b.i.d., twice a day; q.d., once daily.